ARK Genomic Revolution ETF vs Dollar Tree, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $44.61, while Dollar Tree, Inc. trades at $129.5 (market cap $24.61B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Dollar Tree, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | DLTR | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $44.55 | $141.21 |
52-Week Low | $24.02 | $85.04 |
Market Cap | — | $24.61B |
Enterprise Value | — | $31.20B |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.
Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.
Dollar Tree (DLTR) trades at $128.85, down 0.4% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue for 2025 was $17.58 billion, but net income showed a loss of $3.03 billion due to tax impacts, while operating cash flow improved to $2.86 billion. A $2.5 billion share repurchase authorization was announced in July 2026, signaling confidence.
The outlook is mixed: analyst consensus is a Buy with a $126.69 price target, near the current price, but risks include margin pressures from tariffs and volatile profitability. Upside potential exists from cost controls and consumer demand for value, yet investors should monitor Q2 earnings and competitive dynamics closely.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →